Pyrazinamide is indicated for the treatment of active tuberculosis in combination with other antituberculous drugs. It is not recommended for use as monotherapy due to the risk of developing drug-resistant strains of tuberculosis.

TB (Tuberculosis)

• Pyrazinamide should always be administered with other effective antitubercular drugs.
• The recommended dosage of pyrazinamide for adults and children is 15-30 mg/kg/day, given orally once daily. The maximum daily dose should not exceed 2 g. Pyrazinamide should be taken on an empty stomach, at least one hour before or two hours after meals.

The most common adverse reactions associated with pyrazinamide include:

• Gastrointestinal disturbances, such as nausea, vomiting, and abdominal pain
• Hyperuricemia and gout
• Hepatotoxicity
• Photosensitivity and rash
• Arthralgia and myalgia
• Anorexia and weight loss

Nausea

Vomiting

Hyperuricemia

Liver problems

• Pyrazinamide should be used with caution in patients with hepatic impairment, as it can cause hepatotoxicity. Liver function tests should be monitored periodically during treatment.
• Pyrazinamide can cause hyperuricemia and gout, particularly in patients with a history of these conditions. Serum uric acid levels should be monitored regularly during treatment.
• Pyrazinamide can cause photosensitivity and rash. Patients should avoid excessive sunlight or use protective clothing and sunscreen when exposed to sunlight.
• Pyrazinamide should be used with caution in patients with a history of alcohol abuse, as it can exacerbate liver damage.
• Pyrazinamide should not be used in patients with severe renal impairment or gouty arthritis.